End Stage Renal Disease (ESRD) Drug Global Market Report 2023

Description

“End Stage Renal Disease (ESRD) Drug Global Market Report 2023 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on end stage renal disease (esrd) drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
Measure the impact of high global inflation on market growth.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for end stage renal disease (esrd) drug? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The end stage renal disease (esrd) drug market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

1) By Product Type: Calcimimetics; Vitamin D; Sterols; Potassium Binders; Calcium-Based Phosphate Binders; Other Products

2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism; End Stage Renal Disease (ESRD) Induced Hyperphosphatemia; End Stage Renal Disease (ESRD) Induced Hyperkalaemia

3) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy

4) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users

Companies Mentioned: Pfizer Inc.; AstraZeneca Plc.; Sanofi SA; Astellas Pharma Inc.; Novartis AG

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Major players in the end stage renal disease (esrd) drug market are Pfizer Inc., AstraZeneca Plc., Sanofi SA, Astellas Pharma Inc., Novartis AG, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Kissei Pharmaceutical Co. Ltd., Baxter International Inc., AbbVie Inc., Amgen Inc., Akebia Drugs Inc., Bayer AG, and Bristol-Myers Squibb Company.

The global end stage renal disease (ESRD) drug market is expected to grow from $101.73 billion in 2022 to $115.82 billion in 2023 at a compound annual growth rate (CAGR) of 13.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The end stage renal disease (ESRD) drug market is expected to grow to $193.98 billion in 2027 at a CAGR of 13.8%.

The end-stage renal disease (ESRD) drug market consists of sales of cinacalcet hcl, diuretics, sevelamer, epoetin alfa, and over-the-counter drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person's kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).

North America was the largest region in the end stage renal disease (ESRD) drug market in 2022. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The main end stage renal disease (esrd) drugs are calcimimetics, vitamin D, sterols, potassium binders, calcium-based phosphate binders, and others. Calcimimetics can be used to reduce PTH in kidney disease stage 5D, depending on serum calcium and phosphorus levels. The various indications include end stage renal disease (esrd) induced hyperparathyroidism, end stage renal disease (esrd) induced hyperphosphatemia, and end stage renal disease (esrd) induced hyperkalaemia. It is distributed by hospital pharmacy, online pharmacy, and retail pharmacy to be used by hospitals, homecare, specialty clinics, and other end users.

Rising cases of obesity and diabetes are expected to propel the growth of the end-stage renal disease (ESRD) drug market going forward. Obesity is described as abnormal or excessive fat buildup that poses a health concern. In contrast, diabetes is a chronic condition that happens when the pancreas does not create enough insulin or when the body cannot utilize the insulin produced efficiently. In patients with renal disease, managing fluid and electrolyte levels, blood pressure, and waste product elimination through dialysis can improve general health and well-being, which may lead to weight reduction and improve blood sugar control. For instance, in March 2022, according to World Obesity, a US-based membership organization representing national and regional associations dedicated to the study and management of obesity, there were 764 million obese people worldwide in 2020, and this figure is expected to rise to 892 million in 2025 and then to 1,025 million in 2030. Furthermore, in September 2021, according to the International Diabetes Federation (IDF), a Belgium-based umbrella organization of over 230 national diabetes organizations, approximately 537 million individuals (20-79 years of age) were living with diabetes in 2021, with this figure expected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the rising cases of obesity and diabetes will drive the market for end-stage renal disease (ESRD) drugs.

Product innovations are a key trend in gaining popularity in the end-stage renal disease (ESRD) drug market. Major companies operating in the end-stage renal disease (ESRD) drug market are focused on developing innovative solutions to sustain in the market. For instance, in April 2022, GlaxoSmithKline Plc, a UK-based pharmaceutical and biotechnology firm, announced that the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for the possible treatment of patients with chronic kidney disease anaemia (CKD). The new product is based on the unique nobel prize-winning science that proved how cells sense and adapt to oxygen availability.

In November 2021, Vifor Pharma, a Switzerland-based pharma company acquired Sanifit Therapeutics S.A. for an undisclosed amount. With this acquisition, Vifor Pharma expands the company's portfolio of cutting-edge assets. Sanifit Therapeutics S.A. is a Spain-based clinical-stage cardio-renal biopharmaceutical company that specializes in therapies for people with end-stage kidney diseases.

The countries covered in the end stage renal disease (ESRD) drug market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The end stage renal disease (ESRD) drug market research report is one of a series of new reports from The Business Research Company that provides end stage renal disease (ESRD) drug market statistics, including end stage renal disease (ESRD) drug industry global market size, regional shares, competitors with an end stage renal disease (ESRD) drug market share, detailed end stage renal disease (ESRD) drug market segments, market trends and opportunities, and any further data you may need to thrive in the end stage renal disease (ESRD) drug industry. This end stage renal disease (ESRD) drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Product Code: r6662

1. Executive Summary

2. End Stage Renal Disease (ESRD) Drug Market Characteristics

3. End Stage Renal Disease (ESRD) Drug Market Trends And Strategies

4. End Stage Renal Disease (ESRD) Drug Market - Macro Economic Scenario

4.1. COVID-19 Impact On End Stage Renal Disease (ESRD) Drug Market
4.2. Ukraine-Russia War Impact On End Stage Renal Disease (ESRD) Drug Market
4.3. Impact Of High Inflation On End Stage Renal Disease (ESRD) Drug Market

5. End Stage Renal Disease (ESRD) Drug Market Size And Growth

5.1. Global End Stage Renal Disease (ESRD) Drug Historic Market, 2017-2022, $ Billion
- 5.1.1. Drivers Of The Market
- 5.1.2. Restraints On The Market
5.2. Global End Stage Renal Disease (ESRD) Drug Forecast Market, 2022-2027F, 2032F, $ Billion
- 5.2.1. Drivers Of The Market
- 5.2.2. Restraints On the Market

6. End Stage Renal Disease (ESRD) Drug Market Segmentation

6.1. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders
Other Products
6.2. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Indication, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
End Stage Renal Disease (ESRD) Induced Hyperparathyroidism
End Stage Renal Disease (ESRD) Induced Hyperphosphatemia
End Stage Renal Disease (ESRD) Induced Hyperkalaemia
6.3. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospital Pharmacy
Online Pharmacy
Retail Pharmacy
6.4. Global End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End Users

7. End Stage Renal Disease (ESRD) Drug Market Regional And Country Analysis

7.1. Global End Stage Renal Disease (ESRD) Drug Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
7.2. Global End Stage Renal Disease (ESRD) Drug Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

8. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market

8.1. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market Overview
Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
8.3. Asia-Pacific End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

9. China End Stage Renal Disease (ESRD) Drug Market

9.1. China End Stage Renal Disease (ESRD) Drug Market Overview
9.2. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion
9.3. China End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

10. India End Stage Renal Disease (ESRD) Drug Market

10.1. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
10.2. India End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

11. Japan End Stage Renal Disease (ESRD) Drug Market

11.1. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
11.2. Japan End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

12. Australia End Stage Renal Disease (ESRD) Drug Market

12.1. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
12.2. Australia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

13. Indonesia End Stage Renal Disease (ESRD) Drug Market

13.1. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
13.2. Indonesia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

14. South Korea End Stage Renal Disease (ESRD) Drug Market

14.1. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
14.2. South Korea End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

15. Western Europe End Stage Renal Disease (ESRD) Drug Market

15.1. Western Europe End Stage Renal Disease (ESRD) Drug Market Overview
15.2. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
15.3. Western Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

16. UK End Stage Renal Disease (ESRD) Drug Market

16.1. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
16.2. UK End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

17. Germany End Stage Renal Disease (ESRD) Drug Market

17.1. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
17.2. Germany End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

18. France End Stage Renal Disease (ESRD) Drug Market

18.1. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
18.2. France End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

19. Eastern Europe End Stage Renal Disease (ESRD) Drug Market

19.1. Eastern Europe End Stage Renal Disease (ESRD) Drug Market Overview
19.2. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
19.3. Eastern Europe End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

20. Russia End Stage Renal Disease (ESRD) Drug Market

20.1. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
20.2. Russia End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

21. North America End Stage Renal Disease (ESRD) Drug Market

21.1. North America End Stage Renal Disease (ESRD) Drug Market Overview
21.2. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
21.3. North America End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

22. USA End Stage Renal Disease (ESRD) Drug Market

22.1. USA End Stage Renal Disease (ESRD) Drug Market Overview
22.2. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
22.3. USA End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

23. South America End Stage Renal Disease (ESRD) Drug Market

23.1. South America End Stage Renal Disease (ESRD) Drug Market Overview
23.2. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
23.3. South America End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

24. Brazil End Stage Renal Disease (ESRD) Drug Market

24.1. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
24.2. Brazil End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

25. Middle East End Stage Renal Disease (ESRD) Drug Market

25.1. Middle East End Stage Renal Disease (ESRD) Drug Market Overview
25.2. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
25.3. Middle East End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

26. Africa End Stage Renal Disease (ESRD) Drug Market

26.1. Africa End Stage Renal Disease (ESRD) Drug Market Overview
26.2. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By Product Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
26.3. Africa End Stage Renal Disease (ESRD) Drug Market, Segmentation By End User, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

27. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape And Company Profiles

27.1. End Stage Renal Disease (ESRD) Drug Market Competitive Landscape
27.2. End Stage Renal Disease (ESRD) Drug Market Company Profiles
- 27.2.1. Pfizer Inc.
  - 27.2.1.1. Overview
  - 27.2.1.2. Products and Services
  - 27.2.1.3. Strategy
  - 27.2.1.4. Financial Performance
- 27.2.2. AstraZeneca Plc.
  - 27.2.2.1. Overview
  - 27.2.2.2. Products and Services
  - 27.2.2.3. Strategy
  - 27.2.2.4. Financial Performance
- 27.2.3. Sanofi SA
  - 27.2.3.1. Overview
  - 27.2.3.2. Products and Services
  - 27.2.3.3. Strategy
  - 27.2.3.4. Financial Performance
- 27.2.4. Astellas Pharma Inc.
  - 27.2.4.1. Overview
  - 27.2.4.2. Products and Services
  - 27.2.4.3. Strategy
  - 27.2.4.4. Financial Performance
- 27.2.5. Novartis AG
  - 27.2.5.1. Overview
  - 27.2.5.2. Products and Services
  - 27.2.5.3. Strategy
  - 27.2.5.4. Financial Performance

28. Key Mergers And Acquisitions In The End Stage Renal Disease (ESRD) Drug Market

29. End Stage Renal Disease (ESRD) Drug Market Future Outlook and Potential Analysis

30. Appendix

30.1. Abbreviations
30.2. Currencies
30.3. Historic And Forecast Inflation Rates
30.4. Research Inquiries
30.5. The Business Research Company
30.6. Copyright And Disclaimer